A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- Registration Number
- NCT04437511
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.
Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.
- Detailed Description
TRAILBLAZER-ALZ 2 is a Phase 3, double-blind, placebo-controlled study to evaluate the safety and efficacy of N3pG antibody (donanemab) in participants with early symptomatic AD (prodromal AD and mild dementia due to AD) with the presence of brain amyloid and tau pathology.
Following the double-blind 76-week main study period, a double-blind 78-week long-term extension period is added to further evaluate donanemab efficacy and safety over time. Participants from the addendum safety cohort are not eligible for the extension period.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1736
- Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months
- MMSE score of 20 to 28 (inclusive) at baseline
- Meet 18F flortaucipir PET scan (central read) criteria - does not apply to safety cohort
- Meet 18F florbetapir PET scan (central read) criteria
- Have a study partner who will provide written informed consent to participate
- Contraindication to MRI or PET scans
- Current treatment with immunoglobulin G (IgG) therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Participants received placebo given IV. Donanemab Donanemab Participants received 700 milligram (mg) Donanemab every 4 weeks (Q4W) x 3 doses, then 1400 mg Q4W given intravenously (IV) for up to 72 weeks
- Primary Outcome Measures
Name Time Method Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population) Baseline, Week 76 Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population) Baseline, Week 76 Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the ADAS-Cog13 and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. Least Squares (LS) Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline acetylcholinesterase inhibitor (AchI)/Memantine use.
- Secondary Outcome Measures
Name Time Method Change From Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population) Baseline, Week 76 MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.
Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Overall Population) Baseline, Week 76 The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.
Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population) Baseline, Week 76 The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-cog consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.
Change From Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population) Baseline, Week 76 MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.
Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population) Baseline, Week 76 CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, baseline tau category, pooled investigator, and baseline AchI/Memantine use.
Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population) Baseline, Week 76 CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, pooled investigator, and baseline AchI/Memantine use.
Pharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab Week 16 to week 20 The average serum concentration at steady state, calculated as Cav = AUCtau/tau, where tau is the dosing interval (4 weeks). AUCtau/tau was assessed at week 12, 16, 24, 36, 52, 64 and Cav for the dosing interval from week 16 to week 20 is reported.
Number or Participants With Anti-Donanemab Antibodies Baseline through Week 76 Number of participants with treatment-emergent positive Anti-Donanemab antibodies was summarized by treatment group.
Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population) Baseline, Week 76 The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.
Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan Baseline, Week 76 Amyloid PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical brain regions relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, baseline tau category, and age at baseline.
Change From Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan Baseline, Week 76 Flortaucipir PET imaging was used as a quantitative tau biomarker. Tau PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in aggregated tau neurofibrillary tangles (NFTs). Quantitative tau burden was formalized using Standardized Uptake Value Ratio (SUVR) in frontal lobe relative to the cerebellum gray as a reference region. Larger SUVR reflects larger tau burden in the frontal lobe relative to cerebellum gray. LS Mean value was adjusted for baseline score, screening tau category, age and treatment (Type III sum of squares).
Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population) Baseline, Week 76 The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.
Change From Baseline in Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI) Baseline, Week 76 MRI scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in brain volume. Volumetric MRI parameters were measured in bilateral hippocampus, bilateral whole brain, and bilateral ventricles. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline tau category, and age at baseline.
Trial Locations
- Locations (269)
Kaizen Brain Center
🇺🇸La Jolla, California, United States
Ezy Medical Research
🇺🇸Miami, Florida, United States
Columbus Memory Center, LLC
🇺🇸Columbus, Georgia, United States
NeuroStudies
🇺🇸Decatur, Georgia, United States
Medical Corporation Chiseikai Tokyo Center Clinic
🇯🇵Chuo-ku, Tokyo, Japan
Moriyama Neuro Center Hospital
🇯🇵Edogawa-ku, Tokyo, Japan
P-One Clinic
🇯🇵Hachioji, Tokyo, Japan
Irvine Clinical Research
🇺🇸Irvine, California, United States
Gilbert Neurology
🇺🇸Gilbert, Arizona, United States
Xenoscience
🇺🇸Phoenix, Arizona, United States
Banner Alzheimer's Institute
🇺🇸Phoenix, Arizona, United States
Perseverance Research Center
🇺🇸Scottsdale, Arizona, United States
Banner Sun Health Research Institute
🇺🇸Sun City, Arizona, United States
Banner Alzheimer's Institute Tucson
🇺🇸Tucson, Arizona, United States
Center for Neurosciences
🇺🇸Tucson, Arizona, United States
Health Initiatives Research
🇺🇸Fayetteville, Arkansas, United States
North County Neurology Associates
🇺🇸Carlsbad, California, United States
Wr- Pri, Llc
🇺🇸Encino, California, United States
Neuro-Pain Medical Center
🇺🇸Fresno, California, United States
Neurology Center of North Orange County
🇺🇸Fullerton, California, United States
Senior Clinical Trials, Inc.
🇺🇸Laguna Hills, California, United States
Collaborative Neuroscience Research, LLC
🇺🇸Los Alamitos, California, United States
USC Keck School of Medicine
🇺🇸Los Angeles, California, United States
Clinical Research Institute
🇺🇸Los Angeles, California, United States
Neurovations
🇺🇸Napa, California, United States
Hoag Memorial Hospital Presbyterian
🇺🇸Newport Beach, California, United States
Stanford Neuroscience Health Center
🇺🇸Palo Alto, California, United States
SC3 Research - Pasadena
🇺🇸Pasadena, California, United States
PCND Neurology
🇺🇸Poway, California, United States
Anderson Clinical Research
🇺🇸Redlands, California, United States
Artemis Institute for Clinical Research
🇺🇸San Diego, California, United States
Pacific Research Network
🇺🇸San Diego, California, United States
Sharp Neurocognitive Research Center
🇺🇸San Diego, California, United States
UCSF Memory and Aging Center
🇺🇸San Francisco, California, United States
Syrentis Clinical Research
🇺🇸Santa Ana, California, United States
California Neuroscience Research Medical Group, Inc.
🇺🇸Sherman Oaks, California, United States
Tilda Research
🇺🇸Tustin, California, United States
Mountain Neurological Research Center
🇺🇸Basalt, Colorado, United States
Alpine Clinical Research Center
🇺🇸Boulder, Colorado, United States
Colorado Springs Neurological Associates
🇺🇸Colorado Springs, Colorado, United States
Colorado Neurological Research Center, PC
🇺🇸Denver, Colorado, United States
Institute for Neurodegenerative Disorders
🇺🇸New Haven, Connecticut, United States
Yale University, Alzheimer's Disease Research Unit
🇺🇸New Haven, Connecticut, United States
Research Center for Clinical Studies
🇺🇸Norwalk, Connecticut, United States
Ki Health Partners, LLc, dba New England Institute for Clinical Research
🇺🇸Stamford, Connecticut, United States
Georgetown University Medical Center
🇺🇸Washington, District of Columbia, United States
JEM Research Institute
🇺🇸Atlantis, Florida, United States
VIN-Julie Schwartzbard
🇺🇸Aventura, Florida, United States
Neurology Offices of South Florida
🇺🇸Boca Raton, Florida, United States
SFM Clinical Research
🇺🇸Boca Raton, Florida, United States
Brain Matters Research
🇺🇸Stuart, Florida, United States
Cohen Medical Associates
🇺🇸Delray Beach, Florida, United States
Integrity Clinical Research
🇺🇸Doral, Florida, United States
Neuropsychiatric Research Center of Southwest Florida
🇺🇸Fort Myers, Florida, United States
Finlay Medical Research
🇺🇸Miami, Florida, United States
MD Clinical
🇺🇸Hallandale Beach, Florida, United States
AGA Clinical Trials
🇺🇸Hialeah, Florida, United States
Indago Research & Health Center, Inc
🇺🇸Hialeah, Florida, United States
Infinity Clinical Research, LLC
🇺🇸Hollywood, Florida, United States
Encore Research Group- Jacksonville Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
Accel Research Sites - Lakeland Clinical Research Unit
🇺🇸Lakeland, Florida, United States
ClinCloud - Maitland
🇺🇸Maitland, Florida, United States
Merritt Island Medical Research, LLC
🇺🇸Merritt Island, Florida, United States
Mount Sinai Cancer Center
🇺🇸Miami Beach, Florida, United States
Goji Group - Research Trials Group
🇺🇸Miami Lakes, Florida, United States
Homestead Associates in Research
🇺🇸Miami, Florida, United States
Optimus U Corporation
🇺🇸Miami, Florida, United States
Miami Jewish health
🇺🇸Miami, Florida, United States
Future Care Solution
🇺🇸Miami, Florida, United States
Allied Biomedical Research Institute
🇺🇸Miami, Florida, United States
New Horizon Research Center
🇺🇸Miami, Florida, United States
Florida International Research Center
🇺🇸Miami, Florida, United States
Miami Dade Medical Research Institute, LLC
🇺🇸Miami, Florida, United States
The Neurology Research Group
🇺🇸Miami, Florida, United States
VIN-Victor Faradji
🇺🇸Miami, Florida, United States
Collier Neurologic Specialists
🇺🇸Naples, Florida, United States
Suncoast Clinical Research, Inc.
🇺🇸New Port Richey, Florida, United States
Renstar Medical Research
🇺🇸Ocala, Florida, United States
Sensible Healthcare, LLC
🇺🇸Ocoee, Florida, United States
Medical Research Group of Central Florida
🇺🇸Orange City, Florida, United States
Synexus Clinical Research US, Inc.
🇺🇸The Villages, Florida, United States
Headlands Research Orlando
🇺🇸Orlando, Florida, United States
IMIC, Inc.
🇺🇸Palmetto Bay, Florida, United States
Emerald Coast Neurology - Airport Boulevard
🇺🇸Pensacola, Florida, United States
Quantum Laboratories Clinical Research
🇺🇸Pompano Beach, Florida, United States
Progressive Medical Research
🇺🇸Port Orange, Florida, United States
Suncoast Neuroscience Associates, Inc.
🇺🇸Saint Petersburg, Florida, United States
Intercoastal Medical Group
🇺🇸Sarasota, Florida, United States
Roskamp Institute Clinical Trials Division
🇺🇸Sarasota, Florida, United States
Alzheimer's Research and Treatment Center
🇺🇸Wellington, Florida, United States
Tallahassee Neurological Clinic
🇺🇸Tallahassee, Florida, United States
Axiom Clinical Research of Florida
🇺🇸Tampa, Florida, United States
Stedman Clinical Trials
🇺🇸Tampa, Florida, United States
USF Health Byrd Alzheimer's Institute
🇺🇸Tampa, Florida, United States
Charter Research - Lady Lake
🇺🇸The Villages, Florida, United States
Palm Beach Neurology
🇺🇸West Palm Beach, Florida, United States
Conquest Research
🇺🇸Winter Park, Florida, United States
Charter Research - Winter Park
🇺🇸Winter Park, Florida, United States
Gwinnett Research Institute
🇺🇸Buford, Georgia, United States
Center for Advanced Research & Education
🇺🇸Gainesville, Georgia, United States
Northwest Clinical Trials
🇺🇸Boise, Idaho, United States
Great Lakes Clinical Trials - Andersonville
🇺🇸Chicago, Illinois, United States
AMITA Health - Alexian Brothers Neurosciences Institute Clinical Research
🇺🇸Elk Grove Village, Illinois, United States
Advocate Medical Group
🇺🇸Park Ridge, Illinois, United States
Southern Illinois University School of Medicine
🇺🇸Springfield, Illinois, United States
Indiana University
🇺🇸Indianapolis, Indiana, United States
Josephson Wallack Munshower Neurology, PC
🇺🇸Indianapolis, Indiana, United States
McFarland Clinic, PC
🇺🇸Ames, Iowa, United States
Covenant Medical Center
🇺🇸Waterloo, Iowa, United States
The University of Kansas - Clinical Research Center
🇺🇸Fairway, Kansas, United States
College Park Family Care Center/Multi Specialty Clinical Res
🇺🇸Overland Park, Kansas, United States
Cotton O'Neil Clinical Research Center - Central Office
🇺🇸Topeka, Kansas, United States
Ascension Via Christi Research
🇺🇸Wichita, Kansas, United States
Maine Medical Center-Maine Medical Partners Neurology
🇺🇸Scarborough, Maine, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Boston Clinical Trials
🇺🇸Boston, Massachusetts, United States
NECCR PrimaCare Research
🇺🇸Fall River, Massachusetts, United States
BTC Network
🇺🇸New Bedford, Massachusetts, United States
Boston Center for Memory
🇺🇸Newton, Massachusetts, United States
Donald S. Marks M.D., P.C.
🇺🇸Plymouth, Massachusetts, United States
Alzheimers Disease Center
🇺🇸Quincy, Massachusetts, United States
MedVadis Research Corporation
🇺🇸Waltham, Massachusetts, United States
Adams Clinical
🇺🇸Watertown, Massachusetts, United States
QUEST Research Institute
🇺🇸Farmington Hills, Michigan, United States
Precise Research Centers
🇺🇸Flowood, Mississippi, United States
Citizens Memorial Hospital District
🇺🇸Bolivar, Missouri, United States
Clinical Research Professionals
🇺🇸Chesterfield, Missouri, United States
North Kansas City Hospital
🇺🇸North Kansas City, Missouri, United States
Sharlin Health and Neurology
🇺🇸Ozark, Missouri, United States
Arch Clinical Trials
🇺🇸Saint Louis, Missouri, United States
Las Vegas Medical Research
🇺🇸Las Vegas, Nevada, United States
The Cognitive and Research Center of New Jersey
🇺🇸Springfield, New Jersey, United States
Advanced Memory Research Institute of New Jersey
🇺🇸Toms River, New Jersey, United States
Bio Behavioral Health
🇺🇸Toms River, New Jersey, United States
Albany Medical College
🇺🇸Albany, New York, United States
Neurological Associates Albany
🇺🇸Albany, New York, United States
Dent Neurologic Institute
🇺🇸Amherst, New York, United States
University at Buffalo - UBMD Neurology
🇺🇸Buffalo, New York, United States
Clarity Clinical Research
🇺🇸East Syracuse, New York, United States
NYU Langone Health
🇺🇸New York, New York, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
Richmond Behavioral Associates
🇺🇸Staten Island, New York, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
CHS-Behavioral Health Research
🇺🇸Charlotte, North Carolina, United States
Guilford Neurologic Associates, Inc
🇺🇸Greensboro, North Carolina, United States
AMC Research
🇺🇸Matthews, North Carolina, United States
Carteret Medical Group
🇺🇸Morehead City, North Carolina, United States
Accellacare - Winston-Salem
🇺🇸Winston-Salem, North Carolina, United States
NeuroScience Research Center
🇺🇸Canton, Ohio, United States
Valley Medical Research
🇺🇸Centerville, Ohio, United States
Rapid Medical Research
🇺🇸Cleveland, Ohio, United States
Ohio State University
🇺🇸Columbus, Ohio, United States
University of Cincinnati Physicians Company, LLC
🇺🇸Dayton, Ohio, United States
Neurology Diagnostics, Inc.
🇺🇸Dayton, Ohio, United States
IPS Research Company
🇺🇸Oklahoma City, Oklahoma, United States
Lynn Health Science Institute
🇺🇸Oklahoma City, Oklahoma, United States
Central States Research
🇺🇸Tulsa, Oklahoma, United States
Summit Headlands
🇺🇸Portland, Oregon, United States
Center for Cognitive Health
🇺🇸Portland, Oregon, United States
Abington Neurological Associates, Ltd.
🇺🇸Abington, Pennsylvania, United States
Penn Medicine: University of Pennsylvania Health System
🇺🇸Philadelphia, Pennsylvania, United States
Keystone Clinical Studies
🇺🇸Plymouth Meeting, Pennsylvania, United States
Rhode Island Mood & Memory Research Institute
🇺🇸East Providence, Rhode Island, United States
Prism Health Richland Department of Neurology Research
🇺🇸Columbia, South Carolina, United States
Neurology Clinic, P.C.
🇺🇸Cordova, Tennessee, United States
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
🇺🇸Memphis, Tennessee, United States
Senior Adults Specialty Research
🇺🇸Austin, Texas, United States
Gadolin Research
🇺🇸Beaumont, Texas, United States
Kerwin Medical Center
🇺🇸Dallas, Texas, United States
Neurology Consultants of Dallas, PA
🇺🇸Dallas, Texas, United States
InSite Clinical Research
🇺🇸DeSoto, Texas, United States
Houston Methodist Hospital
🇺🇸Houston, Texas, United States
The University of Texas Health Science Center at Houston
🇺🇸Houston, Texas, United States
Central Texas Neurology Consultants
🇺🇸Round Rock, Texas, United States
Glenn Biggs Institute for Alzheimers & Neurodegenerative Diseases
🇺🇸San Antonio, Texas, United States
The Memory Clinic
🇺🇸Bennington, Vermont, United States
Integrated Neurology Services - Falls Church
🇺🇸Arlington, Virginia, United States
Sentara Norfolk General Hospital
🇺🇸Norfolk, Virginia, United States
National Clinical Research, Inc
🇺🇸Richmond, Virginia, United States
Northwest Clinical Research Center
🇺🇸Bellevue, Washington, United States
EvergreenHealth Medical Center
🇺🇸Kirkland, Washington, United States
University of Washington - Harborview Medical Center
🇺🇸Seattle, Washington, United States
Kingfisher Cooperative
🇺🇸Spokane, Washington, United States
Universal Research Group
🇺🇸Tacoma, Washington, United States
Central Coast Neurosciences Research
🇦🇺Erina, New South Wales, Australia
St Vincent's Hospital
🇦🇺Sydney, New South Wales, Australia
HammondCare Greenwich Hospital
🇦🇺Sydney, New South Wales, Australia
KARA Institute for Neurological Diseases
🇦🇺Sydney, New South Wales, Australia
NeuroCentrix
🇦🇺Carlton, Victoria, Australia
Delmont Private Hospital
🇦🇺Glen Iris, Victoria, Australia
HammondCare
🇦🇺Malvern, Victoria, Australia
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
The Royal Melbourne Hospital
🇦🇺Parkville, Victoria, Australia
OCT Research ULC
🇨🇦Kelowna, British Columbia, Canada
True North Clinical Research
🇨🇦New Minas, Nova Scotia, Canada
SKDS Research Inc.
🇨🇦Newmarket, Ontario, Canada
Ottawa Memory Clinic
🇨🇦Ottawa, Ontario, Canada
Bruyère Research Institute
🇨🇦Ottawa, Ontario, Canada
Kawartha Centre - Redefining Healthy Aging
🇨🇦Peterborough, Ontario, Canada
Bluewater Clinical Research Group Inc.
🇨🇦Sarnia, Ontario, Canada
Toronto Memory Program
🇨🇦Toronto, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Baycrest Health Sciences
🇨🇦Toronto, Ontario, Canada
Clinique de la Mémoire de l'Outaouais
🇨🇦Gatineau, Quebec, Canada
MoCA Research and Innovation Inc.
🇨🇦Greenfield Park, Quebec, Canada
Q&T Research Sherbrooke Inc.
🇨🇦Sherbrooke, Quebec, Canada
Diex Recherche Sherbrooke Inc.
🇨🇦Sherbrooke, Quebec, Canada
Alpha Recherche Clinique
🇨🇦Quebec, Canada
ALPHA Recherche Clinique
🇨🇦Quebec, Canada
A-Shine
🇨🇿Pilsen, Plzeň-město, Czechia
Clintrial s.r.o.
🇨🇿Praha, Praha 10, Czechia
Neuropsychiatrie
🇨🇿Prague, Praha 6, Czechia
Neurologická Ambulance - Forbeli
🇨🇿Praha, Praha 6, Czechia
Clinline Services
🇨🇿Hostivice, Středočeský Kraj, Czechia
Brain-Soul Therapy
🇨🇿Kladno, Středočeský Kraj, Czechia
Nagoya Ekisaikai Hospital
🇯🇵Nagoya-shi, Aichi, Japan
Chubu Rosai Hospital
🇯🇵Nagoya, Aichi, Japan
Kojunkai Daido Clinic
🇯🇵Nagoya, Aichi, Japan
National Center for Geriatrics and Gerontology
🇯🇵Obu, Aichi, Japan
Inage Neurology and Memory Clinic
🇯🇵Inage, Chiba, Japan
Matsui e-clinic
🇯🇵Akashi, Hyogo, Japan
Himeji Central Hospital Affiliated Clinic
🇯🇵Himeji, Hyogo, Japan
Kobe University Hospital
🇯🇵Kobe, Hyogo, Japan
Kobe City Medical Center General Hospital
🇯🇵Kobe, Hyogo, Japan
Kakigi Dementia Happiness Clinic
🇯🇵Kobe, Hyogo, Japan
Tokyo Medical University Ibaraki Medical Center
🇯🇵Inashiki, Ibaraki, Japan
Memory Clinic Toride
🇯🇵Toride, Ibaraki, Japan
Yokohama City Minato Red Cross Hospital
🇯🇵Yokohama, Kanagawa, Japan
Oita University Hospital
🇯🇵Yufu, Oita, Japan
Katayama Medical Clinic
🇯🇵Kurashiki, Okayama, Japan
Honmachi Clinic
🇯🇵Ikeda, Osaka, Japan
Takatsuki General Hospital
🇯🇵Takatsuki, Osaka, Japan
Clinical Research Hospital Tokyo
🇯🇵Shinjuku-ku, Tokyo, Japan
Tokyo Metro Bokutoh Hospital
🇯🇵Sumida-ku, Tokyo, Japan
Hiroshima Neurology Clinic
🇯🇵Hiroshima, Japan
Koseikai Takeda Hospital
🇯🇵Kyoto, Japan
Ishikawa Clinic
🇯🇵Kyoto, Japan
National hospital Organization Utano National Hospital
🇯🇵Kyoto, Japan
Oita Prefectural Hospital
🇯🇵Oita, Japan
Itsuki Hospital
🇯🇵Tokushima, Japan
Tokyo Asbo Clinic
🇯🇵Tokyo, Japan
Nippon Medical School Hospital
🇯🇵Tokyo, Japan
Makita General Hospital
🇯🇵Tokyo, Japan
QPS Netherlands B.V
🇳🇱Leeuwarden, Fryslân, Netherlands
Brain Research Center Den Bosch B.V.
🇳🇱's-Hertogenbosch, Noord-Brabant, Netherlands
Brain Research Center
🇳🇱Amsterdam, Noord-Holland, Netherlands
Brain Research Center Zwolle
🇳🇱Zwolle, Overijssel, Netherlands
Ośrodek Badawczo Naukowo Dydaktyczny Chorób Otępiennych Im Księdza Henryka Kardynała Gulbinowicza Uniwersy -T
🇵🇱Scinawa, Dolnośląskie, Poland
Wroclawskie Centrum Alzheimerowskie
🇵🇱Wroclaw, Dolnośląskie, Poland
Centrum Medyczne NEUROMED
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Private Practice - Dr. Urszula Chyrchel- Paszkiewicz
🇵🇱Lublin, Lubelskie, Poland
Centrum Medyczne NeuroProtect
🇵🇱Warsawawa, Mazowieckie, Poland
FutureMeds Warszawa Centrum
🇵🇱Warszawa, Mazowieckie, Poland
Diamond Clinic
🇵🇱Krakow, Małopolskie, Poland
KLIMED Marek Klimkiewicz
🇵🇱Białystok, Podlaskie, Poland
Podlaskie Centrum Psychogeriatrii
🇵🇱Białystok, Podlaskie, Poland
Centrum Badan Klinicznych PI-House sp. z o.o.
🇵🇱Gdansk, Pomorskie, Poland
Centrum Medyczne SENIOR
🇵🇱Sopot, Pomorskie, Poland
Nzoz Neuro-Kard Ilkowski i Partnerzy SPL
🇵🇱Poznan, Wielkopolskie, Poland
Centrum Medyczne Euromedis
🇵🇱Szczecin, Zachodniopomorskie, Poland
Klinika Neuro-Care
🇵🇱Katowice, Śląskie, Poland
SCB Research Center
🇵🇷Bayamon, Puerto Rico
INSPIRA Clinical Research
🇵🇷San Juan, Puerto Rico
Instituto De Neurologia Dra. Ivonne Fraga
🇵🇷San Juan, Puerto Rico
Barbara Diaz-Hernandez MD Research, Inc.
🇵🇷San Juan, Puerto Rico
Glasgow Memory Clinic
🇬🇧Motherwell, Great Britain, United Kingdom
Re:Cognition Health - London
🇬🇧London, London, City Of, United Kingdom
Re:Cognition Health Guildford
🇬🇧Guildford, Surrey, United Kingdom
Re:Cognition Health - Birmingham
🇬🇧Birmingham, United Kingdom